LEADER 04786nam 22005655 450 001 9910493176503321 005 20211021211829.0 010 $a0-520-95858-6 024 7 $a10.1525/9780520958586 035 $a(CKB)3710000000550359 035 $a(EBL)4068976 035 $a(SSID)ssj0001593944 035 $a(PQKBManifestationID)16289341 035 $a(PQKBTitleCode)TC0001593944 035 $a(PQKBWorkID)14880874 035 $a(PQKB)11705529 035 $a(MiAaPQ)EBC4068976 035 $a(DE-B1597)519781 035 $a(OCoLC)1102800346 035 $a(DE-B1597)9780520958586 035 $a(EXLCZ)993710000000550359 100 $a20200424h20162016 fg 0 101 0 $aeng 135 $aurnn#---|u||u 181 $ctxt 182 $cc 183 $acr 200 10$aPublic Health Law $ePower, Duty, Restraint /$fLawrence O. Gostin, Lindsay F. Wiley 205 $a3rd ed. 210 1$aBerkeley, CA :$cUniversity of California Press,$d[2016] 210 4$dİ2016 215 $a1 online resource (763 p.) 300 $aIncludes index. 311 0 $a0-520-28265-5 327 $tFront matter --$tContents --$tIllustrations, Tables, and Boxes --$tForeword --$tPreface to the Third Edition --$tAcknowledgments --$tCHAPTER ONE. A Theory and Definition of Public Health Law --$tCHAPTER TWO. Risk Regulation: A Systematic Evaluation --$tCHAPTER THREE. Public Health Law in the Constitutional Design: Public Health Powers and Duties --$tCHAPTER FOUR. Constitutional Limits on the Exercise of Public Health Powers --$tCHAPTER FIVE. Public Health Governance: Democracy and Delegation --$tCHAPTER SIX. Direct Regulation for the Public's Health and Safety --$tCHAPTER SEVEN. Tort Law and the Public's Health: Indirect Regulation --$tCHAPTER EIGHT. Taxation, Spending, and the Social Safety Net: Hidden Effects on Public Health --$tCHAPTER NINE. Surveillance and Public Health Research: Privacy, Security, and Confidentiality of Personal Health Information --$tCHAPTER TEN. Infectious Disease Prevention and Control --$tCHAPTER ELEVEN. Public Health Emergency Preparedness: Terrorism, Pandemics, and Disasters --$tCHAPTER TWELVE. Promoting Healthier Lifestyles: Noncommunicable Disease Prevention --$tCHAPTER THIRTEEN. Promoting Safer Lifestyles: A Public Health Law Perspective on Accidents and Violence --$tCHAPTER FOURTEEN. Health Justice and the Future of Public Health Law --$tNotes --$tAbout the Authors --$tIndex 330 $aLawrence O. Gostin's seminal Public Health Law is widely acclaimed as the definitive statement on public health law at the turn of the twenty-first century. In this bold third edition, Gostin is joined by Lindsay F. Wiley to analyze major health threats of our time such as chronic diseases, emerging infectious diseases, antimicrobial resistance, bioterrorism, natural disasters, opioid overdose, and gun violence. The authors draw on constitutional law, administrative law, local government law, and tort law to develop their conception of law as a tool for protecting the public's health. The book creates an intellectual framework for modern public health law and supports that framework with illustrations of the scientific, political, and ethical issues involved. In proposing innovative solutions for the future of the public's health, Gostin and Wiley's essential study provides a blueprint for public and political debates to come. New issues covered in this edition: ? Corporate personhood rights raised in response to regulations of tobacco, food and beverages, alcohol, firearms, prescription drugs, and marijuana. ? Local government authority to protect the public's health. ? Deregulation and harm reduction as modes of public health law intervention. ? Taxation, spending, and alteration of the socioeconomic environment as modes of public health law intervention. ? Access to health care as a strategy for protecting the public's health. ? Taxation, spending, licensing, zoning, and shared-use strategies for chronic disease prevention. ? The public health law perspective on violence and injury prevention. ? Health justice as a framework for reducing health disparities and protecting the public's health. 606 $aPublic health laws$zUnited States 606 $aPublic health$xMoral and ethical aspects 608 $aElectronic books. 615 0$aPublic health laws 615 0$aPublic health$xMoral and ethical aspects. 676 $a344.7304 700 $aGostin$b Lawrence O.$4aut$4http://id.loc.gov/vocabulary/relators/aut$0884710 702 $aWiley$b Lindsay F.$4aut$4http://id.loc.gov/vocabulary/relators/aut 801 0$bDE-B1597 801 1$bDE-B1597 906 $aBOOK 912 $a9910493176503321 996 $aPublic Health Law$92443891 997 $aUNINA LEADER 05814nam 2201729z- 450 001 9910557546203321 005 20210501 035 $a(CKB)5400000000044145 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69451 035 $a(oapen)doab69451 035 $a(EXLCZ)995400000000044145 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aNovel Biomarkers for Heart Disease 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 online resource (420 p.) 311 08$a3-03943-883-2 311 08$a3-03943-884-0 330 $aCardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease pathways that are involved in a broad spectrum of cardiac disease conditions ranging from acute coronary syndrome, to heart failure (and heart failure with preserved ejection fraction, HFpEF), to pulmonary hypertension or arrhythmias. In this Special Issue, we will provide an overview of the current developments in the field of biomarker research, beginning with research on molecular pathways and cellular communication (e.g., microRNA) up to the clinical use of biomarkers. 606 $aMedicine$2bicssc 610 $aacute kidney injury 610 $aacute myocardial infarction 610 $aAMI 610 $aaneurysm 610 $aaortic disease 610 $aaortic regurgitation 610 $aatrial fibrillation 610 $aatrial myopathy 610 $abiomarker 610 $abiomarkers 610 $acarbohydrate antigen-125 610 $acardiac biomarkers 610 $acardiac intensive care units 610 $acardiac magnetic resonance imaging 610 $acardiometabolic disease 610 $acardiometabolic risks 610 $acardiovascular death 610 $acardiovascular diseases 610 $acardiovascular events 610 $acardiovascular risk 610 $acardiovascular surgery 610 $acatestatin 610 $acell adhesion molecule 610 $aceramides 610 $aceruloplasmin 610 $achronic heart failure 610 $achronic kidney disease 610 $acirculating cells 610 $acirculating miRNAs 610 $aCKD 610 $acohort studies 610 $acoronary artery disease 610 $aCVD 610 $adiet quality 610 $aechocardiography 610 $aejection fraction 610 $aepicardial adipose tissue 610 $aepicardial fat 610 $aepicardial fat volume 610 $aFABP3 610 $afatty acid-binding protein 3 610 $aFramingham risk score 610 $aGDF-15 610 $aGDF8 610 $agrowth differentiation factor 15 (GDF-15) 610 $aH-FABP 610 $ahealthy eating index 610 $aheart failure 610 $aheart failure decompensation 610 $aheart-type fatty acid-binding protein 610 $aheart-type fatty acid-binding protein (H-FABP) 610 $aherat failure 610 $aHF 610 $aHFpEF 610 $aHFrEF 610 $ahypertension 610 $ainflammatory marker 610 $aKLF4 610 $aleft ventricular adverse remodelling 610 $aleft ventricular ejection fraction 610 $aleft ventricular systolic function 610 $aliver-type fatty-acid-binding protein 610 $along-term outcomes 610 $alongitudinal strain 610 $amagnetic resonance imaging 610 $amagnetic resonance spectroscopy 610 $ametabolic syndrome 610 $amicroRNA 610 $amiRNA 610 $amitochondrial DNA (mtDNA) 610 $amitochondrial dysfunction 610 $amuscle wasting 610 $amyocardial infarction 610 $amyocardial triglyceride content 610 $amyostatin 610 $an/a 610 $aNAFLD 610 $aNAFLD fibrosis score 610 $aNT-proBNP 610 $aNYHA functional class 610 $aobesity 610 $aolder women 610 $aoperative risk 610 $aoxidative stress 610 $aPBMCS 610 $aPentraxin-3 610 $aplatelets 610 $aPPCI 610 $apregnancy-associated plasma protein-A 610 $aprimary prevention 610 $areactive oxygen species (ROS) 610 $arenal dysfunction 610 $arepeated measurements 610 $arisk prediction 610 $arisk stratification 610 $asaliva 610 $asalivary biomarkers 610 $asarcopenia 610 $asecondary prevention 610 $aSOCE 610 $asoluble suppression of tumorigenicity 2 (sST2) 610 $asoluble urokinase-type plasminogen activator receptor (suPAR) 610 $asST2 610 $aSTEMI 610 $aSTIM1 610 $asudden cardiac death 610 $asuPAR 610 $asynthetic phenotype 610 $aT1 mapping 610 $aTGF-? pathway 610 $athyroid-stimulating hormone 610 $atroponin 610 $avena contracta area 610 $aventricular arrhythmia 610 $aventricular tachycardia 610 $avery low-density lipoprotein 615 7$aMedicine 700 $aLichtenauer$b Michael$4edt$01287943 702 $aLichtenauer$b Michael$4oth 906 $aBOOK 912 $a9910557546203321 996 $aNovel Biomarkers for Heart Disease$93020593 997 $aUNINA